93 related articles for article (PubMed ID: 2054790)
21. [Urokinase-type plasminogen activator (uPA), uPA receptor (uPA-R) and inhibitors (PA I -1) expression in hepatocellular carcinoma in relation to cancer invasion/metastasis and prognosis].
Zheng Q; Tang Z; Wu Z
Zhonghua Zhong Liu Za Zhi; 1998 Jan; 20(1):57-9. PubMed ID: 10921061
[TBL] [Abstract][Full Text] [Related]
22. [Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone].
Li H; Dong S; Zeng Y
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):386-8. PubMed ID: 11810768
[TBL] [Abstract][Full Text] [Related]
23. Prevention of metastasis by inhibition of the urokinase receptor.
Crowley CW; Cohen RL; Lucas BK; Liu G; Shuman MA; Levinson AD
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5021-5. PubMed ID: 8389464
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of plasma tissue factor pathway and urokinase-type plasminogen activator system in cancer patients.
Zhao W; Wang X; Qu B; Huang X; Wang H
Chin Med J (Engl); 2002 May; 115(5):702-4. PubMed ID: 12133538
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of genetically diagnosed lymph node micrometastasis in non-small cell lung carcinoma cases.
Hashimoto T; Kobayashi Y; Ishikawa Y; Tsuchiya S; Okumura S; Nakagawa K; Tokuchi Y; Hayashi M; Nishida K; Hayashi S; Hayashi J; Tsuchiya E
Cancer Res; 2000 Nov; 60(22):6472-8. PubMed ID: 11103815
[TBL] [Abstract][Full Text] [Related]
26. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
[TBL] [Abstract][Full Text] [Related]
27. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR
Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206
[TBL] [Abstract][Full Text] [Related]
28. Border between N1 and N2 stations in lung carcinoma: lessons from lymph node metastatic patterns of lower lobe tumors.
Okada M; Sakamoto T; Yuki T; Mimura T; Nitanda H; Miyoshi K; Tsubota N
J Thorac Cardiovasc Surg; 2005 Apr; 129(4):825-30. PubMed ID: 15821650
[TBL] [Abstract][Full Text] [Related]
29. Relationship between circulating plasminogen activators and tumor development in mice.
Colombi M; Rebessi L; Boiocchi M; Barlati S
Cancer Res; 1986 Nov; 46(11):5748-53. PubMed ID: 3093069
[TBL] [Abstract][Full Text] [Related]
30. Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
Sier CF; Quax PH; Vloedgraven HJ; Verheijen JH; Griffioen G; Ganesh S; Lamers CB; Verspaget HW
Invasion Metastasis; 1993; 13(6):277-88. PubMed ID: 7860221
[TBL] [Abstract][Full Text] [Related]
31. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer.
Zlobec I; Minoo P; Baumhoer D; Baker K; Terracciano L; Jass JR; Lugli A
Cancer; 2008 Feb; 112(3):495-502. PubMed ID: 18076013
[TBL] [Abstract][Full Text] [Related]
32. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
33. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor.
Rofstad EK; Rasmussen H; Galappathi K; Mathiesen B; Nilsen K; Graff BA
Cancer Res; 2002 Mar; 62(6):1847-53. PubMed ID: 11912164
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer.
Ohta S; Fuse H; Fujiuchi Y; Nagakawa O; Furuya Y
Anticancer Res; 2003; 23(3C):2945-50. PubMed ID: 12926141
[TBL] [Abstract][Full Text] [Related]
36. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.
Duffy MJ; Reilly D; O'Sullivan C; O'Higgins N; Fennelly JJ; Andreasen P
Cancer Res; 1990 Nov; 50(21):6827-9. PubMed ID: 2119883
[TBL] [Abstract][Full Text] [Related]
37. Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases.
Schoppmeyer K; Frühauf N; Oldhafer K; Seeber S; Kasimir-Bauer S
Oncol Rep; 2006 Feb; 15(2):449-54. PubMed ID: 16391868
[TBL] [Abstract][Full Text] [Related]
38. Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression.
Berney CR; Yang J; Fisher RJ; Russell PJ; Crowe PJ
Oncol Res; 1998; 10(1):47-54. PubMed ID: 9613457
[TBL] [Abstract][Full Text] [Related]
39. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Shapiro RL; Duquette JG; Roses DF; Nunes I; Harris MN; Kamino H; Wilson EL; Rifkin DB
Cancer Res; 1996 Aug; 56(15):3597-604. PubMed ID: 8758932
[TBL] [Abstract][Full Text] [Related]
40. Enhanced urokinase-type plasminogen activator activity by extracellular matrix protein obtained from highly metastatic human lung adenocarcinoma cell line.
Hagiya Y; Fukao H; Ueshima S; Okada K; Inufusa H; Kamiishi H; Matsuo O
Clin Chim Acta; 1996 Sep; 253(1-2):37-50. PubMed ID: 8879837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
